The goal of this clinical research study is to see if imatinib mesylate (Gleevec, STI571) can
improve CML in chronic phase.
Objectives:
Primary Objective:
To increase the proportion of patients achieving a complete cytogenetic response in patients
with Ph-positive early chronic phase CML using initial Gleevec therapy.
Secondary Objective:
To evaluate the duration of cytogenetic response, duration of hematologic response and
survival.